Otonomy, Inc. Logo
Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting
October 27, 2021 07:30 ET | Otonomy, Inc.
Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss Supportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection...
Otonomy, Inc. Logo
Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
October 12, 2021 07:30 ET | Otonomy, Inc.
Results published in Otology & Neurotology, a leading journal in fieldOTO-313 was well-tolerated and demonstrated a statistically significant higher proportion of responders than placebo across...
Otonomy, Inc. Logo
Otonomy to Participate in Two Upcoming Investor Conferences
September 02, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Appoints Jill Broadfoot to Board of Directors
August 19, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 04, 2021 16:16 ET | Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022OTO-413 Phase 1/2 trial expansion in hearing loss ongoing with results expected in mid-2022OTO-825 preclinical...
Otonomy, Inc. Logo
Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update
July 28, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy, Inc. Logo
Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss
June 15, 2021 07:30 ET | Otonomy, Inc.
OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests in dose escalation efficacy cohortExpansion study will support endpoint selection...
Otonomy, Inc. Logo
Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021 16:17 ET | Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in...
Otonomy, Inc. Logo
Otonomy Announces Proposed Public Offering
April 07, 2021 16:06 ET | Otonomy, Inc.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus
March 25, 2021 07:30 ET | Otonomy, Inc.
Phase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for primary efficacy endpointPatient enrollment criteria refined to enrich...